Apolipoprotein A-I mimetics and high-density lipoprotein function

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 19, Issue 2, 2012, Pages 109-114

  Gordon, Scott M ^a   Davidson, William S ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

apolipoprotein A I; atherosclerosis; high density lipoprotein; mimetic peptide

Indexed keywords

4F PEPTIDE; 5A PEPTIDE; ABC TRANSPORTER A1; ABC TRANSPORTER G1; APOLIPOPROTEIN A1; ARACHIDONATE 12 LIPOXYGENASE; ARYLDIALKYLPHOSPHATASE 1; CD11B ANTIGEN; ELK PEPTIDE; ETC 642; HIGH DENSITY LIPOPROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN; MANGANESE SUPEROXIDE DISMUTASE; MONOCYTE CHEMOTACTIC PROTEIN 1; SERUM AMYLOID A; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; AORTA ATHEROSCLEROSIS; ASTHMA; ATHEROSCLEROSIS; CARDIOMYOPATHY; CELL PROLIFERATION; CELL VIABILITY; CHOLESTEROL TRANSPORT; CHRONIC INFLAMMATION; DRUG EFFICACY; HUMAN; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; INSULIN SENSITIVITY; INTESTINE; INTRAVASCULAR ULTRASOUND; LIPID STORAGE; LUNG LAVAGE; MACROPHAGE; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN FUNCTION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; ANTI-INFLAMMATORY AGENTS; APOLIPOPROTEIN A-I; ASTHMA; ATHEROSCLEROSIS; HUMANS; HYPOLIPIDEMIC AGENTS; LIPOPROTEINS, HDL; MICE;

EID: 84858276052     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0b013e32835056d4     Document Type: Review

References (25)

1. Gordon SM, Hofmann S, Askew DS, Davidson WS. High density lipoprotein: it's not just about lipid transport anymore. Trends Endocrinol Metab 2011; 22:9-15.
2. Osei-Hwedieh DO, Amar M, Sviridov D, Remaley AT. Apolipoprotein mimetic peptides: mechanisms of action as antiatherogenic agents. Pharmacol Ther 2011; 130:83-91. This is an excellent review of the long-term progress and development of apoA-I mimetic peptides.
3. Sethi AA, Stonik JA, Thomas F, et al. Asymmetry in the lipid affinity of bihelical amphipathic peptides. A structural determinant for the specificity of ABCA1- dependent cholesterol efflux by peptides. J Biol Chem 2008; 283:32273-32282.
4. Amar MJ, D'Souza W, Turner S, et al. 5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice. J Pharmacol Exp Ther 2010; 334:634-641.
5. Iwata A, Miura SI, Zhang B, et al. Antiatherogenic effects of newly developed apolipoprotein A-I mimetic peptide/phospholipid complexes against aortic plaque burden in Watanabe-heritable hyperlipidemic rabbits. Atherosclerosis 2011; 218:300-307.
6. D'Souza W, Stonik JA, Murphy A, et al. Structure/function relationships of apolipoprotein a-I mimetic peptides: implications for antiatherogenic activities of high-density lipoprotein. Circ Res 2010; 107:217-227. In this study a variety of structural changes were introduced into bihelical apoA-I mimetic peptides to probe the effects of changes in structure on the capacity of the peptides to perform various beneficial functional processes.
7. Sviridov DO, Ikpot IZ, Stonik J, et al. Helix stabilization of amphipathic peptides by hydrocarbon stapling increases cholesterol efflux by the ABCA1 transporter. Biochem Biophys Res Commun 2011; 410:446-451. This study presents a novel approach to the stabilization of a mimetic peptide while at the same time increasing the efficiency of cholesterol efflux, a major protective mechanism.
8. Navab M, Anantharamaiah GM, Hama S, et al. Oral administration of an Apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 2002; 105:290-292. (Pubitemid 34106174)
9. Di Bartolo BA, Nicholls SJ, Bao S, et al. The apolipoprotein A-I mimetic peptide ETC-642 exhibits anti-inflammatory properties that are comparable to high density lipoproteins. Atherosclerosis 2011; 217:395-400.
10. Nicholls SJ, Dusting GJ, Cutri B, et al. Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation 2005; 111:1543-1550. (Pubitemid 40470651)
11. Kelesidis T, Yang OO, Currier JS, et al. HIV-1 infected patients with suppressed plasma viremia on treatment have pro-inflammatory HDL. Lipids Health Dis 2011; 10:35.
12. Vaziri ND, Bai Y, Yuan J, et al. ApoA-1 mimetic peptide reverses uremia-induced upregulation of pro-atherogenic pathways in the aorta. Am J Nephrol 2010; 32:201-211.
13. Ganapathy E, Su F, Meriwether D, et al. D-4F, an apoA-I mimetic peptide, inhibits proliferation and tumorigenicity of epithelial ovarian cancer cells by upregulating the antioxidant enzyme MnSOD. Int J Cancer 2012; 130:1071-1081.
14. Su F, Kozak KR, Imaizumi S, et al. Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. Proc Natl Acad Sci U S A 2010; 107:19997-20002. These studies indicate the potential for apoA-I and its mimetic peptides to protect against tumor development in a mouse model for cancer.
15. Gao F, Vasquez SX, Su F, et al. L-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGF/basic FGF signaling pathways. Integr Biol (Camb) 2011; 3:479-489.
16. Yao X, Dai C, Fredriksson K, et al. 5A, an apolipoprotein A-I mimetic peptide, attenuates the induction of house dust mite-induced asthma. J Immunol 2011; 186:576-583. In a common mouse model for asthma, here the 5A peptide inhibits inflammation in the lungs preventing the development of airway hyperresponsiveness and airway remodeling.
17. Dai L, Datta G, Zhang Z, et al. The apolipoprotein A-I mimetic peptide 4F prevents defects in vascular function in endotoxemic rats. J Lipid Res 2010; 51:2695-2705.
18. van Lenten BJ, Wagner AC, Jung CL, et al. Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I. J Lipid Res 2008; 49:2302-2311.
19. Woo JM, Lin Z, Navab M, et al. Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis. Arthritis Res Ther 2010; 12:R93.
20. Morgantini C, Imaizumi S, Grijalva V, et al. Apolipoprotein A-I mimetic peptides prevent atherosclerosis development and reduce plaque inflammation in a murine model of diabetes. Diabetes 2010; 59:3223-3228.
21. Peterson SJ, Drummond G, Kim DH, et al. L-4F treatment reduces adiposity, increases adiponectin levels, and improves insulin sensitivity in obese mice. J Lipid Res 2008; 49:1658-1669.
22. Vecoli C, Cao J, Neglia D, et al. Apolipoprotein A-I mimetic peptide L-4F prevents myocardial and coronary dysfunction in diabetic mice. J Cell Biochem 2011; 112:2616-2626.
23. Navab M, Reddy ST, Anantharamaiah GM, et al. Intestine may be a major site of action for the apoA-I mimetic peptide 4F whether administered subcutaneously or orally. J Lipid Res 2011; 52:1200-1210. This study compared the efficacy of oral vs. subcutaneous administration of the mimetic 4F and found that although about 1000-fold higher plasma levels are achieved with subcutaneous administration, both administration routes result in very similar degress of efficacy as measured by several methods. Also, the amount of peptide in feces is similar by either route, suggesting the intestine as a poteintial site of action.
24. Watson CE, Weissbach N, Kjems L, et al. Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function. J Lipid Res 2011; 52:361-373.
25. Bloedon LT, Dunbar R, Duffy D, et al. Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J Lipid Res 2008; 49:1344-1352.